Precigen highlights pipeline updates to be presented at the 42nd annual j.p. morgan healthcare conference

–   prgn-2012 phase 2 pivotal study data in rrp is anticipated in the second quarter of 2024; the company plans to submit a bla under an accelerated approval pathway in the second half of 2024; commercial readiness preparations are underway for a potential launch in 2025  – –   company presentation scheduled for january 10 at 5:15 pm pst – germantown, md. , jan. 8, 2024 /prnewswire/ -- precigen, inc. (nasdaq: pgen), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today released highlights of pipeline updates to be presented at the 42nd annual j.p.
PGEN Ratings Summary
PGEN Quant Ranking